AngioLab, Inc. is Korean Biotechnology Company established in June 1999, developing pharmaceutical products based on angiogenesis inhibition to treat and/or prevent various angiogenesis-dependent diseases, such as cancers, ocular diseases, abdominal obesity, psoriasis and arthritis.
AngioLab focuses at this stage on 3 products: abdominal obesity; functional dietary supplement for abdominal obesity; functional cosmeceuticals and Wrinklestat.
Exit: Sale of shares 2018
http://www.angiolab.co.kr
AngioLab focuses at this stage on 3 products: abdominal obesity; functional dietary supplement for abdominal obesity; functional cosmeceuticals and Wrinklestat.
Exit: Sale of shares 2018
http://www.angiolab.co.kr
Investors 3
| Date | Name | Website |
| - | Company K ... | kpartners.... |
| - | Agate Medi... | agate-inve... |
| - | Neoplux | shinhanvc.... |
Mentions in press and media 1
| Date | Title | Description |
| 17.11.2021 | Angiolab, Inc. announced that it expects to receive KRW 5.499987 billion in funding from Smart CKD Bio-Healthcare No.1 Venture Investment Association, New Wave No. 6 Investment Association, Sori Asset... | Angiolab, Inc. announced a private placement of 578,946 registered convertible preference shares at an issue price of KRW 9,500 per share for gross proceeds of KRW 5,499,987,000 on November 17, 2021. The par value of the shares to be issued... |